(Q41904942)

English

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

scientific article published on 25 February 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 October 2017

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study (English)

1 reference

Europe PubMed Central

13 October 2017

zoledronic acid

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

1

object named as

Karim Fizazi

1 reference

Europe PubMed Central

13 October 2017

author name string

Michael Carducci

2

1 reference

Europe PubMed Central

13 October 2017

Matthew Smith

3

1 reference

Europe PubMed Central

13 October 2017

Ronaldo Damião

4

1 reference

Europe PubMed Central

13 October 2017

Janet Brown

5

1 reference

Europe PubMed Central

13 October 2017

Lawrence Karsh

6

1 reference

Europe PubMed Central

13 October 2017

Piotr Milecki

7

1 reference

Europe PubMed Central

13 October 2017

Neal Shore

8

1 reference

Europe PubMed Central

13 October 2017

Michael Rader

9

1 reference

Europe PubMed Central

13 October 2017

Huei Wang

10

1 reference

Europe PubMed Central

13 October 2017

Qi Jiang

11

1 reference

Europe PubMed Central

13 October 2017

Sylvia Tadros

12

1 reference

Europe PubMed Central

13 October 2017

Roger Dansey

13

1 reference

Europe PubMed Central

13 October 2017

Carsten Goessl

14

1 reference

Europe PubMed Central

13 October 2017

language of work or name

0 references

publication date

25 February 2011

1 reference

Europe PubMed Central

13 October 2017

1 reference

Europe PubMed Central

13 October 2017

377

1 reference

Europe PubMed Central

13 October 2017

813-822

1 reference

Europe PubMed Central

13 October 2017

9768

1 reference

Europe PubMed Central

13 October 2017

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Treatment and prevention of bone complications from prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Cancer statistics, 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Role of targeted therapy in the treatment of advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Estimates of cancer incidence and mortality in Europe in 2008.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Histopathological assessment of prostate cancer bone osteoblastic metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

New research findings on zoledronic acid: survival, pain, and anti-tumour effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Significance and impact of bisphosphonate-induced acute phase responses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Osteoclast differentiation and activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Bone markers in the management of patients with skeletal metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

5 June 2018

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

18 August 2018

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

18 August 2018

Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

18 August 2018

Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

18 August 2018

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

18 August 2018

Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090685

18 August 2018

Economic burden of metastatic bone disease in the U.S.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962344-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Some fundamental issues with non-inferiority testing in active controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962344-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Cox's Regression Model for Counting Processes: A Large Sample Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962344-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962344-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 tria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962344-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone

1 reference

https://pubmed.ncbi.nlm.nih.gov/21353695

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/S0140-6736(10)62344-6

1 reference

Europe PubMed Central

13 October 2017

1 reference

Europe PubMed Central

13 October 2017

1 reference

Europe PubMed Central

13 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41904942&oldid=1929667671"